Merck & Co., Inc. has lowered its prices in developing countries for its 2 HIV drugs

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1279, 2001-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Merck & Co. has substantially cut the price of 2 of its antiretroviral agents in Mexico

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Merck & Co., Inc.: analysis of patenting 1998 – 2002

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 7, 2003-07 ,pp. : 1037-1044

Informa Healthcare

Access to resources Recommend Favorite

If the EU has its way, developing countries without domestic facilities to manufacture pharmaceuticals on their own

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 355, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Merck Sharpe and Dohme has launched new formulations for all dosage strengths of its NSAID etoricoxib [Arcoxia]

Inpharma, Vol. 1, Iss. 1538, 2006-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Peginterferon- -2a (40kD) Plus Ribavirin: A Review of its Use in Hepatitis C Virus and HIV Co-infection

By Plosker Greg L. Keating Gillian M.

Drugs, Vol. 64, Iss. 24, 2004-01 ,pp. : 2823-2843

Adis International

Access to resources Recommend Favorite